[Transplacental passage of the antiviral agent, bonafton].
The ability of 14C-bonafton to penetrate the placental bar was studied in female Wistar rats. The drug was shown to penetrate through the placenta in insignificant amounts. The maximal quantities of the drug which entered the fetuses proper during the last third of pregnancy do not exceed 0.55% of 14C-bonafton content in the mother's blood. It was revealed that bonafton transplacental penetration is barred by fetal envelopes.
D000653:Amniotic Fluid / Q000187:drug effects; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002250:Carbon Radioisotopes; D005321:Extraembryonic Membranes / Q000187:drug effects; D005260:Female; D005333:Fetus / Q000187:drug effects; D005865:Gestational Age; D008431:Maternal-Fetal Exchange / Q000187:drug effects*; D009285:Naphthoquinones / Q000494:pharmacology*; D010920:Placenta / Q000187:drug effects; D011247:Pregnancy; D051381:Rats; D013997:Time Factors
D000998:Antiviral Agents; D002250:Carbon Radioisotopes; D009285:Naphthoquinones; C011180:bonafton
Issledovanie transplatsentarnogo perekhoda protivovirusnogo preparata bonaftona.